Mizuho Securities has slightly increased its price target for Amylyx Pharmaceuticals to $39 from $38, while reiterating its Outperform rating. This adjustment follows the company's Q3 2026 earnings report, suggesting a modestly positive re-evaluation by the analyst firm.
Mizuho Securities has raised its price target for Amylyx Pharmaceuticals (AMLX) from $38 to $39, maintaining an Outperform rating. This minor adjustment comes after the company's third-quarter 2026 earnings release. While a price target increase is generally positive, the small magnitude of the change suggests a limited immediate market impact. For traders, this indicates a continued positive sentiment from Mizuho, but it's unlikely to be a significant short-term catalyst. The long-term implications depend on whether this reflects a broader positive trend in analyst sentiment or specific company performance that warrants further upside.